The estimated Net Worth of John Pappajohn is at least $5.04 Milion dollars as of 23 May 2019. Mr. Pappajohn owns over 200,000 units of Cancer Genetics stock worth over $5,041,842 and over the last 12 years he sold CGIX stock worth over $0. In addition, he makes $0 as Non-Executive Chairman of the Board at Cancer Genetics.
Sign up
Mr. Pappajohn CGIX stock SEC Form 4 insiders trading
John has made over 33 trades of the Cancer Genetics stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 200,000 units of CGIX stock worth $250,000 on 23 May 2019.
The largest trade he's ever made was buying 1,000,000 units of Cancer Genetics stock on 31 January 2019 worth over $230,000. On average, John trades about 76,253 units every 38 days since 2013. As of 23 May 2019 he still owns at least 1,117,925 units of Cancer Genetics stock.
You can see the complete history of Mr. Pappajohn stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Pappajohn biography
John G. Pappajohn is Non-Executive Chairman of the Board of Cancer Genetics, Inc. In 1969, Mr. Pappajohn is the chairman of our Board and is a pioneer in the venture capital industry. In 1969, Mr. Pappajohn founded Equity Dynamics, Inc., a financial consulting entity, and Pappajohn Capital Resources, a venture capital firm, both in Des Moines, Iowa. Mr. Pappajohn has been involved in over 100 start-up companies and has served as a director of over 40 public companies, many in the bioscience and health-related industries. He currently serves on the boards of the following public companies: American CareSource Holdings, Inc., since 2004, and CNS Response, since 2009. Previously, Mr. Pappajohn served on the boards of ConMed Healthcare Management, Inc. from 2005 until August 2012, PharmAthene, Inc., from 2007 until July 2011, Careguide, Inc., from 1995 until 2010, and SpectraScience, Inc., from 2007 until 2009. Mr. Pappajohn has a BSC degree in business from the University of Iowa.
How old is John Pappajohn?
John Pappajohn is 90, he's been the Non-Executive Chairman of the Board of Cancer Genetics since 2014. There are no older and 7 younger executives at Cancer Genetics.
What's John Pappajohn's mailing address?
John's mailing address filed with the SEC is 201 ROUTE 17 NORTH, 2ND FLOOR, C/O CANCER GENETICS, INC., RUTHERFORD, NJ, 07070.
Insiders trading at Cancer Genetics
Over the last 12 years, insiders at Cancer Genetics have traded over $1,720,897 worth of Cancer Genetics stock and bought 3,891,559 units worth $4,573,241 . The most active insiders traders include John Pappajohn, Tommy G Thompson a John A Roberts. On average, Cancer Genetics executives and independent directors trade stock every 35 days with the average trade being worth of $340,207. The most recent stock trade was executed by John A Roberts on 31 January 2019, trading 185,436 units of CGIX stock currently worth $42,650.
What does Cancer Genetics's logo look like?
Complete history of Mr. Pappajohn stock trades at Cancer Genetics
Cancer Genetics executives and stock owners
Cancer Genetics executives and other stock owners filed with the SEC include:
-
Jane Houldsworth,
Vice President - Research & Development -
Franklyn Prendergast,
Independent Director -
Howard McLeod,
Independent Director -
Edmund Cannon,
Independent Director -
Thomas Widmann,
Director -
Geoffrey Harris,
Director -
John Roberts,
President, Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer -
John Pappajohn,
Non-Executive Chairman of the Board -
Panna Sharma,
Chief Executive Officer -
Raju S.K. Chaganti,
Director -
Michael J. Welsh,
Director -
Edward J Sitar,
Chief Financial Officer -
Igor Gitelman,
Chief Accounting Officer -
Michael Brian Mc Cartney,
Chief Commercial Officer -
Michael Glenn Miles,
Chief Financial Officer -
Ralf Brandt,
President, Discovery Services -
Rita Shaknovich,
VP of Hematopathology Services -
Paul Rothman,
Director -
Keith L Brownlie,
Director -
Andrew L Pecora,
Director -
Tommy G Thompson,
Director -
Steven Hepburn,
VP of Biopharma Marketing